Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon May 17, 2023 10:09am
179 Views
Post# 35452252

RE:Partner Time

RE:Partner TimeYes, Promis needs to partner they do not have the Management structure in place to go into the clinic and to many things can go sideways.  Compare small Acumen who has one product in the clinic and no others in the fire like ALS or PD. Promis has approx- 10 staff in management - 5 of them employees, half of them like the head of toxicology for preparing pmn 310. Acumen has 35-40 people in mpt many different positions like directors and vp's of regulatory affairs, clinical operations, chief legal officer etc, many staff directly for supporting the clinic trial. 

Promis needs a partner that can provide all the different resources needed for running a clinical trial and big partner clout when challenges arrise!

<< Previous
Bullboard Posts
Next >>